CAJ | 학술논문

目的：观察肾康注射液治疗慢性肾脏疾病( CKD 3~4期)的临床疗效。方法：96例患者分为两组,试验组给予肾康注射液100 ml+10%葡萄糖(或者0.9%氯化钠注射液)300 ml静脉滴注每日1次,对照组给予前列地尔注射液5μg+生理盐水10 ml静脉注射每日1次,疗程为14 d,监测治疗前后患者的血肌酐( Scr)、尿素氮( BUN)、肌酐清除率( Ccr)、中医症候积分等指标变化情况。结果：与自身基线水平相比,治疗后两组患者Scr、BUN、Ccr、中医症候积分均有明显变化,比较差异有统计学意义(P<0.05),试验组总有效率为54.17%,对照组总有效率为56.25%,两组比较差异无统计学意义。结论：肾康注射液能有效延缓中医辨证分型为湿浊证和(或)血瘀证CKD3~4期患者病程的进展。
목적：관찰신강주사액치료만성신장질병( CKD 3~4기)적림상료효。방법：96례환자분위량조,시험조급여신강주사액100 ml+10%포도당(혹자0.9%록화납주사액)300 ml정맥적주매일1차,대조조급여전렬지이주사액5μg+생리염수10 ml정맥주사매일1차,료정위14 d,감측치료전후환자적혈기항( Scr)、뇨소담( BUN)、기항청제솔( Ccr)、중의증후적분등지표변화정황。결과：여자신기선수평상비,치료후량조환자Scr、BUN、Ccr、중의증후적분균유명현변화,비교차이유통계학의의(P<0.05),시험조총유효솔위54.17%,대조조총유효솔위56.25%,량조비교차이무통계학의의。결론：신강주사액능유효연완중의변증분형위습탁증화(혹)혈어증CKD3~4기환자병정적진전。
Objective:To observe the efficacy of Alprostadil and Shenkang in the treatment of chronic kidney disease (CKD,stage 3~4). Methods:96 cases of CKD(stage 3 ~4) patients were divided into two group:shenkang group(48 patients) were given 100 ml Shenkang which was dissolved in 300 ml 10% glucose solution/0. 9% sodium chloride injection once a day; Al-prostadil group(48 patients) were treated with 5 μg Alprostadil Injection which was dissolved in 10 ml 0. 9% sodium chloride injec-tion once a day, its efficacy and safety would be evaluated after treatment for 14 days. Contrast the concentration of the serum creati-nine, blood urea nitrogen. Creatinine Clearance Rate and serum lipid, lipoprotein, the scores of traditional Chinese medical syn-drome, before and after the treatment. Results:After treatment, the clearance rate of Scr and Ccr of the patients were improved signif-icantly (P<0. 05) in two group. The overall effective rate of shenkang group was 54. 17% and the overall effective rate of Alprostadil group achieved 56. 25%, but no differences were found between the two groups (P>0. 05). Conclusion:Shenkang Injection has an abvious therapeutic effect on CKD (stage 3~4) presented damp retardarced symptom and/or blood stasissed symptom.